The global artemisinin combination therapy (ACT) market size is expected to reach USD 697.9 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. Rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.
Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.
For PDF sample Copy or More Details please visit link @: https://www.grandviewresearch.com/industry-analysis/artemisinin-combination-therapy-act-market
Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.
WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.
Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.
Further key findings from the report suggest:
• AL was the largest segment in 2017 due to the fact that it was the first ACT to be marketed and prequalified by WHO for its efficacy, safety, and quality. It is available in more than 60 countries and is the only ACT approved by U.S. FDA
• MEA held the largest share in the market for ACTs due to growing initiatives by government and non-government organizations to raise awareness
• Asia Pacific also held a prominent position in the market owing to factors such as large production base of artemisinin herbs coupled with rising access to ACT in this region
• Major players operating in the market are Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals
• Key players are adopting different strategies to increase their market share such as increasing geographic presence, R & D, new product development, and indication extension.
To request research report sample copy with TOC please visit @: https://www.grandviewresearch.com/industry-analysis/artemisinin-combination-therapy-act-market/request/rs1
Grand View Research has segmented the global artemisinin combination therapy market on the basis of type and region:
Artemisinin Combination Therapy Type Outlook (Revenue, USD Million, 2014 - 2025)
• Artemether-Lumefantrine
• Artesunate-Amodiaquine
• Dihydroartemisinin-Piperaquine
• Artesunate-Mefloquine
• Artesunate-Sulfadoxine-Pyrimethamine
• Pyronaridine-Artesunate
Artemisinin Combination Therapy Regional Outlook (Revenue, USD Million, 2014 - 2025)
• Asia Pacific
o China
o India
o Pakistan
o Indonesia
o Vietnam
• Latin America
o Brazil
o Colombia
• Middle East & Africa
o Nigeria
o Democratic Republic of Congo
o Mali
o Uganda
o Kenya
For Inquire before buying please visit @: https://www.grandviewresearch.com/inquiry/5414/ibb
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.